BioXcel Therapeutics Past Earnings Performance
Past criteria checks 0/6
BioXcel Therapeutics's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 82.4% per year.
Key information
-22.9%
Earnings growth rate
-13.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 82.4% |
| Return on equity | n/a |
| Net Margin | -3,119.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioXcel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -71 | 40 | 34 |
| 30 Jun 24 | 2 | -108 | 57 | 49 |
| 31 Mar 24 | 2 | -153 | 73 | 68 |
| 31 Dec 23 | 1 | -179 | 83 | 84 |
| 30 Sep 23 | 1 | -212 | 94 | 107 |
| 30 Jun 23 | 1 | -203 | 87 | 109 |
| 31 Mar 23 | 1 | -187 | 79 | 100 |
| 31 Dec 22 | 0 | -166 | 69 | 91 |
| 30 Sep 22 | 0 | -137 | 62 | 71 |
| 30 Jun 22 | 0 | -122 | 60 | 61 |
| 31 Mar 22 | 0 | -112 | 56 | 56 |
| 31 Dec 21 | 0 | -107 | 55 | 52 |
| 30 Sep 21 | 0 | -102 | 52 | 51 |
| 30 Jun 21 | 0 | -100 | 44 | 80 |
| 31 Mar 21 | 0 | -94 | 34 | 60 |
| 31 Dec 20 | 0 | -82 | 25 | 58 |
| 30 Sep 20 | 0 | -69 | 16 | 53 |
| 30 Jun 20 | 0 | -54 | 10 | 19 |
| 31 Mar 20 | 0 | -41 | 9 | 32 |
| 31 Dec 19 | 0 | -33 | 8 | 26 |
| 30 Sep 19 | 0 | -32 | 7 | 25 |
| 30 Jun 19 | 0 | -28 | 6 | 22 |
| 31 Mar 19 | 0 | -22 | 6 | 17 |
| 31 Dec 18 | 0 | -19 | 5 | 15 |
| 30 Sep 18 | 0 | -15 | 5 | 10 |
| 30 Jun 18 | 0 | -11 | 4 | 7 |
| 31 Mar 18 | 0 | -8 | 3 | 5 |
| 31 Dec 17 | 0 | -5 | 2 | 3 |
Quality Earnings: BX2 is currently unprofitable.
Growing Profit Margin: BX2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BX2 is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.
Accelerating Growth: Unable to compare BX2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BX2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: BX2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.